EQ-5D as a measure of programme outcome: Results from the Singapore early psychosis intervention programme

Psychiatry Research

Volumn 215, Issue 1, 2014, Pages 46-51

  Subramaniam, Mythily ^a   Abdin, Edimansyah ^a   Poon, Lye Yin ^a   Vaingankar, Janhavi Ajit ^a   Lee, Helen ^a   Chong, Siow Ann ^a   Verma, Swapna ^a  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

Author keywords

Duration of untreated Psychosis; Early psychosis; EQ 5D; Remission; Singapore

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DEMOGRAPHY; EUROQOL 5D; FEMALE; FOLLOW UP; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; REMISSION; SINGAPORE; TREATMENT DURATION;

DURATION OF UNTREATED PSYCHOSIS; EARLY PSYCHOSIS; EQ-5D; REMISSION; SINGAPORE;

ADOLESCENT; ADULT; FEMALE; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOTIC DISORDERS; QUALITY OF LIFE; QUESTIONNAIRES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SINGAPORE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892887939     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2013.10.002     Document Type: Article

References (50)

1. Abdin E., Subramaniam M., Vaingankar J.A., Nan L., Chong S.A. Measuring health-related quality of life among adults in Singapore: population norms for the EQ-5D. Qual. Life Res. 2013, 2013(April):3. (Epub ahead of print).
2. Addington J., Young J., Addington D. Social outcome in early psychosis. Psychol. Med. 2003, 33:1119-1124.
3. Addington J., Van Mastrigt S., Addington D. Duration of untreated psychosis: impact on 2-year outcome. Psychol. Med. 2004, 34:277-284.
4. Adewuya A.O., Makanjuola R.O. Subjective life satisfaction and objective living conditions of patients with schizophrenia in Nigeria. Psychiatry Serv. 2010, 61:314-316.
5. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 162:441-449.
6. Angermeyer M.C., Holzinger A., Kilian R., Matschinger H. Quality of life-as defined by schizophrenic patients and psychiatrists. Int. J. Soc. Psychiatry 2001, 47:34-42.
7. Auquier P., Simeoni M.C., Sapin C., Reine G., Aghababian V., Cramer J., Lancon C. Development and validation of a patient-based health related quality of life questionnaire in schizophrenia: the S-QoL. Schizophr. Res. 2003, 63:137-149.
8. Austin P.C. A comparison of methods for analyzing health-related quality-of-life measures. Value Health 2002, 5:329-337.
9. Awad A.G., Voruganti L.N. Intervention research in psychosis: issues related to the assessment of quality of life. Schizophr. Bull. 2000, 26:557-564.
10. Badia X., Roset M., Herdman M., Kind P. A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med. Decis. Making 2001, 21:7-16.
11. Barnes T.R., Leeson V.C., Mutsatsa S.H., Watt H.C., Hutton S.B., Joyce E.M. Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br. J. Psychiatry 2008, 193:203-209.
12. Barton G.R., Hodgekins J., Mugford M., Jones P.B., Croudace T., Fowler D. Measuring the benefits of treatment for psychosis: validity and responsiveness of the EQ-5D. Br. J. Psychiatry 2009, 195:170-177.
13. Bechdolf A., Pukrop R., Köhn D., Tschinkel S., Veith V., Schultze-Lutter F., Ruhrmann S., Geyer C., Pohlmann B., Klosterkötter J. Subjective quality of life in subjects at risk for a first episode of psychosis: a comparison with first episode schizophrenia patients and healthy controls. Schizophr. Res. 2005, 79:137-143.
14. Bobes J., García-Portilla P., Sáiz P.A., Bascarán T., Bousoño M. Quality of life measures in schizophrenia. Eur. Psychiatry 2005, 20:S313-S317.
15. Carr, V., Neil, A., Halpin, S., Holmes, S., 2002. Costs of Psychosis in Urban Australia. A Bulletin of the Low Prevalence Disorders Study, National Survey of Mental Health and Wellbeing. Available online at http://www.health.gov.au/internet/main/publishing.nsf/Content/3C7E39B92E056E60CA257229001704E6/File/costcov.pdf.
16. Chong S.A., Lee C., Bird L., Verma S. A risk reduction approach for schizophrenia: the early psychosis intervention programme. Ann. Acad. Med. Singap. 2004, 33:630-635.
17. Chong S.A. Mental health in Singapore: a quiet revolution?. Ann. Acad. Med. Singap. 2007, 36:795-796.
18. Dolan P. Modelling valuations for EuroQol health states. Med. Care 1997, 35:1095-1108.
19. Doyle M., Flanagan S., Browne S., Clarke M., Lydon D., Larkin C., O'Callaghan E. Subjective and external assessments of quality of life in schizophrenia: relationship to insight. Acta Psychiatr. Scand. 1999, 99:466-472.
20. Drummond M.F., O'Brien B., Stoddart G.L., Torrance G.W. Methods for the Economic Evaluation of Health Care Programmes 1997, Oxford University Press, Oxford, UK.
21. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV) 1996, American Psychiatric Press, Inc, Washington, D.C.
22. Fitzgerald P.B., Williams C.L., Corteling N., Filia S.L., Brewer K., Adams A., de Castella A.R., Rolfe T., Davey P., Kulkarni J. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr. Scand. 2001, 103:387-392.
23. Forster M. Predictive accuracy as an achievable goal of science. Philos. Sci. 2002, 69:S124-S134.
24. Cost-effectiveness in Health and Medicine 1996, Oxford University Press, New York. M.R. Gold, J.E. Siegal, L.B. Russell, M.C. Weinstein (Eds.).
25. Goldman H.H., Skodol A.E., Lave T.R. Revising axis V for DSM-IV: a review of measures of social functioning. Am. J. Psychiatry 1992, 149:1148-1156.
26. Greiner W., Claes C., Busschbach J.J., von der Schulenburg J.M. Validating the EQ-5D with time trade-off for the German population. Eur. J. Health Econ. 2005, 6:124-130.
27. Harvey P.D., Green M.F., Keefe R.S., Velligan D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J. Clin. Psychiatry 2004, 65:361-372.
28. Herrman H., Hawthorne G., Thomas R. Quality of life assessment in people living with psychosis. Soc. Psychiatry Psychiatr. Epidemiol. 2002, 37:510-518.
29. Huang I.C., Frangakis C., Atkinson M.J., Willke R.J., Leite W.L., Vogel W.B., Wu A.W. Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease. Health Serv. Res. 2008, 43:327-339.
30. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
31. Manca A., Hawkins N., Sculpher M.J. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2005, 14:487. (486).
32. McGorry P.D. The recognition and optimal management of early psychosis: an evidence-based reform. World Psychiatry 2002, 1:76-83.
33. McGorry P.D., Killackey E.J. Early intervention in psychosis: a new evidence based paradigm. Epidemiol. Psichiatr. Soc. 2002, 11:237-247.
34. Oliver J.P.J., Huxley P.J., Priebe S., Kaiser W. Measuring the quality of life of severely mentally ill people using the Lancashire quality of life profile. Soc. Psychiatry Psychiatr. Epidemiol. 1997, 32:76-83.
35. Patrick D.L., Erickson.P. Health Status and Health Policy 1993, Oxford University Press, New York.
36. Payakachat N., Summers K.H., Pleil A.M., Murawski M.M., Thomas J., Jennings K., Anderson J.G. Predicting EQ-5D utility scores from the 25-item National Eye Institute Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related macular degeneration. Qual. Life Res. 2009, 18:801-813.
37. Powell J.L. Least absolute deviations estimation for the censored regression model. J. Econom. 1984, 25:303. (235).
38. Prieto L., Sacristan J.A., Hormaechea J.A., Casado A., Badia X., Gomez J.C. Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr. Med. Res. Opin. 2004, 20:827-835.
39. Pyne J.M., Patterson T.L., Kaplan R.M., Gillin J.C., Koch W.L., Grant I. Assessment of quality of life of patients with major depression. Psychiatr. Serv. 1997, 48:224-230.
40. Ritsner M.S. The distress/protection vulnerability model of quality of life impairment syndrome. Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorders. New Perspectives on Research and Treatment 2007, 3-19. Springer, London. M.S. Ritsner, A.G. Awad (Eds.).
41. Saarni S.I., Viertiö S., Perälä J., Koskinen S., Lönnqvist J., Suvisaari J. Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders. Br. J. Psychiatry 2010, 197:386-394.
42. Savilla K., Kettler L., Galletly C. Relationships between cognitive deficits, symptoms and quality of life in schizophrenia. Aust. N. Z. J. Psychiatry 2008, 42:496-504.
43. Singapore Department of Statistics. Singapore in Figures, 2012. Available online at (last assessed on 11 October 2012). http://www.singstat.gov.sg/pubn/reference/sif2012.pdf.
44. Stochl J., Croudace T., Perez J., Birchwood M., Lester H., Marshall M., Amos T., Sharma V., Fowler D, Jones P.B. Usefulness of EQ-5D for evaluation of health-related quality of life in young adults with first-episode psychosis. Qual. Life Res. 2013, 1055-1063. The National Eden Study Team, (Epub ahead of print).
45. Sullivan P.W., Ghushchyan V. Mapping the EQ-5D Index from the SF-12: US general population preferences in a nationally representative sample. Med. Decis. Making 2006, 26:401-409.
46. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208. The EuroQol Group.
47. Tobin J. Estimation of relationships for limited dependent variables. Econometrica 1958, 26:24-26.
48. Verma S., Subramaniam M., Abdin E., Poon L.Y., Chong S.A. Symptomatic and functional remission in patients with first-episode psychosis. Acta Psychiatr. Scand. 2012, 126:282-289.
49. Voruganti L., Heslegrave R., Awad A.G., Seeman M.V. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol. Med. 1998, 28:165-172.
50. Development of the WHOQOL: rationale and current status. Int. J. Ment. Health 1994, 23:24-56. WHOQOL Group.